Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention
SAN DIEGO, June 12, 2014 /PRNewswire/ — Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), announced today that Cardium Therapeutics will announce interim results on the Generx(®) angiogenic gene therapy product candidate international ASPIRE Phase 3 registration study at the 2014 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year’s global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego, California. The presentation will be made by Cardium’s chief executive officer Christopher Reinhard on June 24, 2014, and will also be made available through the Company’s website on that day.
Cardium will report on safety and efficacy data from the randomized, multi-center, controlled study’s primary registration endpoint of improvement in microvascular cardiac perfusion (blood flow), with Generx compared to the control group in patients with cardiac microvascular insufficiency, which is based on a diagnosis of myocardial ischemia as measured by cardiac imaging. The ASPIRE clinical study represents the fifth clinical study under the Generx gene therapy worldwide development program, which when completed will have evaluated over 780 patients at over 100 medical centers in the United States, Western Europe, South America, Canada and the Russian Federation, and is considered the largest cardiac gene therapy registration dossier in the world.
About Taxus Cardium Pharmaceuticals Group
Taxus Cardium Pharmaceuticals Group Inc. is a publicly-listed holding company that operates Cardium Therapeutics a development stage advanced regenerative therapeutics company that is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics including (1) Generx(®), an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of patients with cardiac microvascular insufficiency with myocardial ischemia due to advanced coronary artery disease; and (2) Excellagen(®), an FDA-cleared flowable dermal matrix designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics (www.excellagen.com). For more information about Taxus Cardium’s product development activities visit www.cardiumthx.com.
About the BIO International Convention
The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit convention.bio.org.
Except for statements of historical fact, the matters discussed in this press release and in the Company’s corresponding presentation are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2014 Cardium Therapeutics, Inc. All rights reserved.
Cardium Therapeutics(®), Generx(®), Cardionovo(®), Tissue Repair(TM), Excellagen(®), Excellarate(TM), Genedexa(TM), and LifeAgain(TM), are trademarks of Cardium Therapeutics, Inc., Tissue Repair Company or LifeAgain Insurance Solutions Inc. Other trademarks belong to their respective owners.
SOURCE Taxus Cardium Pharmaceuticals Group